Company Analysis
Sign in

BioCryst Pharmaceuticals, Inc. (BCRX)

Nasdaq: BCRX · Biological Products, (No Diagnostic Substances) · Durham, NC · filing with the SEC since 1995
Full chart Alerts Compare
Grade6.1
◀ Past 6.3● Present 5.6▶ Future 6.4
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

83 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to BioCryst Pharmaceuticals, Inc.’s names, not what it holds today.

Patents granted
83
83 utility, 1976 to Dec 31, 2025
Granted in 2025
3
Against 7 in 2024 and 9 in 2023
Applications published
102
12 of them in 2025
Names they are printed under
3
its own name, a subsidiary
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals18
Organic fine chemistry13
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name3 counted
BioCryst Pharmaceuticals, Inc. its own name
US, as the owner printed on each patent. 5 more under the same name are not counted (printed in GB)
83 granted
29 published
BioCryst Pharmaceuticals, Inc. its own name
named as the applicant on its applications, in US
0 granted
70 published
Astria Therapeutics, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
3 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 23, 202512,503,443Process-scale synthesis of a plasma kallikrein inhibitorOrganic fine chemistryBioCryst Pharmaceuticals, Inc.
Dec 2, 202512,485,109Pyrrolo 12.3-dipyrimidine compounds and analogues thereofOrganic fine chemistryBioCryst Pharmaceuticals, Inc.
Jul 1, 202512,344,585Crystalline salts of a plasma kallikrein inhibitorPharmaceuticalsBioCryst Pharmaceuticals, Inc.
Dec 10, 202412,162,838Human plasma kallikrein inhibitorsPharmaceuticalsBioCryst Pharmaceuticals, Inc.
Oct 22, 202412,121,503Antiviral treatmentsPharmaceuticalsBioCryst Pharmaceuticals, Inc.
Oct 15, 202412,116,346Human plasma kallikrein inhibitorsPharmaceuticalsBioCryst Pharmaceuticals, Inc.
Aug 6, 202412,054,492Imidazole-containing inhibitors of ALK2 kinaseOrganic fine chemistryBioCryst Pharmaceuticals, Inc.
Jul 23, 202412,043,610Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitorsOrganic fine chemistryBioCryst Pharmaceuticals, Inc.
May 7, 202411,975,003Methods and compositions for treatment of Zika virus infectionPharmaceuticalsBioCryst Pharmaceuticals, Inc.
Jan 9, 202411,866,418Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitorsOrganic fine chemistryBioCryst Pharmaceuticals, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 25, 20252025/0388549CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITORPharmaceuticalsBioCryst Pharmaceuticals, Inc.
Dec 25, 20252025/0388548CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITORPharmaceuticalsBioCryst Pharmaceuticals, Inc.
Dec 25, 20252025/0388547CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITORPharmaceuticalsBioCryst Pharmaceuticals, Inc.
Dec 25, 20252025/0388546CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITORPharmaceuticalsBioCryst Pharmaceuticals, Inc.
Dec 25, 20252025/0388545CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITORPharmaceuticalsBioCryst Pharmaceuticals, Inc.
Dec 11, 20252025/0376448CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITORPharmaceuticalsBioCryst Pharmaceuticals, Inc.
Dec 11, 20252025/0376447CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITORPharmaceuticalsBioCryst Pharmaceuticals, Inc.
Nov 20, 20252025/0353921AFFINITY MATURED ANTI-OX40 ANTIBODIES AND USE THEREOFBiotechnologyAstria Therapeutics, Inc.
Sep 4, 20252025/0275991ORAL COMPLEMENT FACTOR D INHIBITORSOrganic fine chemistryBioCryst Pharmaceuticals, Inc.
Aug 28, 20252025/0270171HUMAN PLASMA KALLIKREIN INHIBITORSPharmaceuticalsBioCryst Pharmaceuticals, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 17 · Organic fine chemistry 5 · Biotechnology 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton BCRX · research, not advice